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Isolation, Cloning, Expression and Immunoactivity of
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Background: Iron, an essential element for bacterial life.
Native FepB functions in the periplasm to facilitate the
transfer of ferric enterobactin through the two- protein
inner membrane channel FepDG into cytoplasm by FepC
catalyzed ATP hydrolysis. These data support the idea that
production of antibody against FepB may contribute to pro-
tection against gram negative bacteria. The present study
was designed to identify, produce and immunoactivate the
periplasmic binding protein, FepB from Escherichia coli
O157:H7
Methods: The gene coding for ferric enterobactin biding
protein from E. coli O157:H7 was ampliﬁed. This gene was
cloned and expressed as C-terminal His(6)-tagged protein.
Results: The SDS-PAGE analysis of the total protein
revealed only two distinct bands, with molecular masses of
31 kDa and 34 kDa. The Ni-NTA chromatography puriﬁed FepB
and the osmotically shocked periplasmic fraction of IPTG
induced cells showed only a single band of 31 kDa. Polyclonal
mouse antibody was raised against the recombinant protein
during 4 weeks after immunization. Western blot analysis
of the recombinant FepB with mouse antiserum revealed a
single band of 31 kDa. Polyclonal antibody raised against the
recombinant protein reacted with bacterial FepB.
Conclusion: Identiﬁcation and puriﬁcation of FepB helped
reveal its appropriate molecular mass. Reaction of the
recombinant FepB antiserum with bacterial FepB ﬁnds its
immunoactive contribution to protection against gram neg-
ative bacteria harbouring the FepB protein. The successful
production of antibody by periplasmic product of FepB gene
can ﬁnd a room for further research aimed at broad spec-
trum vaccines production.
doi:10.1016/j.ijid.2008.05.682
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Immunogenicity of Recombinant Omp28 from Brucella
Melitensis in Mice
P. Kaushik ∗, P. Chaudhury, G. Shukla, D.K. Singh
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Recombinant Omp28 (r-Omp28) from Brucella meliten-
sis produced in Escherichia coli was previously identiﬁed
as group 3 proteins. In this study, we evaluated the
immunogenicity of r-Omp28 in mice. This r-Omp28 was
injected intramuscularly in the mice with and without CpG
oligodeoxynucleotides (ODN). The booster was given on 3rd
week with the same antigenic preparation. Speciﬁc anti-
bodies to puriﬁed r-Omp28 were detected in mice sera
by western blotting and indirect ELISA (iELISA). In addi-
tion, isotype (IgG1 and IgG2a) speciﬁc antibodies were also
measured by iELISA. Cellular immune response was mea-
sured by lymphocyte proliferation assay (MTT assay) after
in vitro stimulation of spleenocytes by r-Omp28. Immu-
nization with r-Omp28 induced a vigorous immunoglobulin
G (IgG) response, with higher IgG1 than IgG2a. Whereas,
immunization of mice with rOmp28 +CpG induced IgG2a
dominated response, suggesting the induction of a T helper
1 (Th1) response by CpG ODN. Spleenocyte from immunized
mice showed signiﬁcant proliferative response (3 week post
booster), but it was higher (P < 0.05) in r-Omp28 +CpG than
r-Omp28 immunized mice. Our results indicate that r-Omp28
is a good immunogen, capable of inducing both humoral and
cellular immune response. The humoral response was biased
towards Th1 type when it was co-administered with CpG
ODN.
doi:10.1016/j.ijid.2008.05.683
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Lassa virus (LASV) is the cause of widespread human
infection in West Africa that occasionally develops into Lassa
Fever (LF) and is responsible for the deaths of thousands of
people each year. The ‘‘at risk’’ LASV sero-negative pop-
ulation in the region may be as high as 200million. In the
general population the case fatality rate is 1-2% and can be
as high as 15—30% among hospitalized patients. The sizeable
disease burden, numerous imported cases worldwide, and
possibility that LASV can be used as an agent of biological
warfare make a strong case for vaccine development.
Reassortant technology was used to make ML29 virus
encoding the major antigens (NP and GPC) of LASV and
the RNA polymerase and Z protein of Mopeia virus (MOPV),
a naturally attenuated virus genetically related to LASV.
Plaque puriﬁcation and restricted numbers of cell culture
passages resulted in eighteen mutations distinguishing the
ML29 genome from the parental LASV and MOPV strains.
These mutations additionally contributed to the attenuated
phenotype.
In the current study we evaluated safety, immunogenic-
ity, and efﬁcacy of the ML29 reassortant vaccine using
a recently-established human LF model in common mar-
mosets, Callithrix jacchus. We have shown that a single
injection of ML29 induced low, transient viremia and ML29
replicated at low or moderate levels in target tissues
depending on dose of the vaccination. Exposure of human
PBMC with ML29 and MOPV has been used as an additional
safety test. The gene expression patterns of ML29-exposed
cells and control, mock-exposed cells, clustered together
and maintained a signiﬁcant distance from the MOPV group.
A single ML29 vaccination induced speciﬁc and non-speciﬁc
immune responses and completely protected monkeys in
challenge experiments against fatal LF by induction of ster-
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ilizing immune responses. ML29 is a promissing vaccine to
control LF in West Africa.
doi:10.1016/j.ijid.2008.05.684
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Targeting Burkholderia pseudomallei Immunogenic Pro-
teins as Potential Prophylactic Agents Against Melioidosis
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Burkholderia pseudomallei is the etiological agent of
melioidosis, a severe invasive disease of humans and ani-
mals in subtropical areas and northern Australia. There is
an urgent need to develop effective therapeutic molecules
against the pathogen for better management of melioidosis.
We undertook to survey for all potential B. pseudoma-
llei immunogenic proteins in order to dissect the bacterial
pathogenesis and evaluate vaccine candidates. In the
present study, a B. pseudomallei clinical isolate (D286)
genomic expression library was constructed and 109 sero-
reactive clones were identiﬁed from the library screened
with pooled melioidosis patients’ sera. DNA sequence
analysis of the seropositive clones revealed 109 putative
immunogenic proteins that were annotated and delin-
eated into functional classes of cell envelope components,
protein secretion and cell motility, transcription, amino
acid transport and metabolism, inorganic ion transport
and metabolism, energy production, protein metabolism,
nucleic acid metabolism and repair, unknown function hypo-
thetical proteins, and other metabolism and transporter
proteins. The complete open reading frame of an immuno-
genic putative outer membrane protein (Oma) was cloned,
expressed and shown to maintain immuno-reactivity with
patient sera. Up to 80% of BALB/c mice immunized with
recombinant Oma were protected from infectious chal-
lenge with 10xLD50 of B. pseudomallei D286, compared with
non-immunized mouse. Therefore, the utility of Oma as a
potential prophylactic agent for melioidosis is proposed.
Mouse anti-Oma polyclonal serum conﬁrmed the presence of
wild type Oma in B. pseudomallei lysate. In addition, pro-
tein sequence analysis revealed that Oma is a member of the
Omp85 family and is highly conserved among species within
the Burkholderia genus, suggesting its suitability as a univer-
sal vaccine candidate or diagnostic epitope for Burkholderia
spp. Characterization of the B. pseudomallei immunome has
shed new light on unraveling the bacterium’s pathogenic
mechanism and disease severity. These immunogens can be
further evaluated as vaccine and serodiagnostic candidates
as well as drug targets.
doi:10.1016/j.ijid.2008.05.685
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Background: It is known that the attenuated polio vac-
cine viruses derived from oral poliovirus vaccine undergo
neurovirulent reversion during repeated replication in the
human alimentary tract, and some paralytic cases caused by
the revertants have been reported. Furthermore, the rever-
tants are excreted with the feces into the environment, and
the viruses have caused new epidemics of poliomyelitis in
the world. It is an obstacle for the achievement of polio
eradication program.
Objective: In this study, to elucidate the reversion mech-
anism of polio vaccine virus to the neurovirulent genotype in
the human alimentary tract, an accumulation of the rever-
sion of the vaccine viruses passaged in cultivation cells which
were derived from the human alimentary tract was ana-
lyzed.
Methods: Polio vaccine viruses were passaged three times
in Caco-2 cells derived from human colon carcinoma. The
reversion of the passaged viruses was analyzed by the
‘‘mutant analysis by PCR and restriction enzyme cleavage
(MAPREC)’’ method designated to estimate the ratio of
revertants in a virus population.
Results: The accumulation of reversion in the vaccine
viruses increased rapidly with viruses passaged at a tem-
perature of 37 ◦C compared with those at 34 ◦C. However,
it was hardly observed in viruses passaged in HEp-2 cells
which were derived from human laryngeal carcinoma at a
temperature of 37 ◦C.
Conclusion: A large difference was observed in the fre-
quency of reversion between Caco-2 and HEp-2 cells though
both cells were derived from human carcinoma. It is impor-
tant to elucidate the cellular factors which take part in the
reversion frequency of the virus genome. Such research is
expected to lead to the elucidation of the reversion mecha-
nism and to the development of a controlling expedient for
the neurovirulent reversion of the polio vaccine virus.
doi:10.1016/j.ijid.2008.05.686
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Current egg-based inﬂuenza vaccine production technol-
ogy is labor-intensive and lack of ﬂexibility and its capacity
would not be able to meet the demand during inﬂuenza
pandemics. Therefore, vaccine production using mammalian
cell technology is becoming viable and attractive. The cur-
rent inﬂuenza H5N1 vaccine strain (NIBRG-14) could grow
efﬁciently in chicken embroyonated eggs and MDCK cells
